前往化源商城

19573-01-4 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1158_MLP
Protocol: A 5 mL overnight pre-culture of E. coli is started by inoculating a tube of lysogeny broth with a single colony from an agar plate. The tube is incubated at 37 degrees C overnight with shaking. The resulting saturated culture is removed from the shaker and diluted into fresh lysogeny broth at 1:100 proportion and incubated at 37 degrees C with shaking for two hours. The culture is removed from the shaker and absorbance is measured at 600 nm. The culture is diluted into fresh lysogeny broth to an estimated absorbance of 0.0002. For each library plate to be screened, two 384-well assay plates are filled with 30 microL per well of fresh lysogeny broth, except for the positive control columns, which are left empty. The multiple of two is necessary to expose the strain in duplicate to the same compounds from a given library plate.

300 nL of experimental compounds are transferred into the assay plates from library plates using a robotically manipulated stainless steel pin array, exposing the strain to the same compounds at the same concentration. The positive control columns are filled with 30 microL of the positive control compound in LB. Thirty microL of E. coli culture at absorbance of 0.0002 are then added to the assay plates, producing a total volume of 60 microL in each well. Plates are incubated at 37 degrees C without shaking and with humidification for 23 hours. The plates are removed from the incubator, and absorbance of the cultures is measured at 600 nm using a PerkinElmer EnVision plate reader. The absorbance is used as the readout.

Positive control: (R)-4-(4-(2-fluoro-4-methoxyphenyl)-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide was present at 0.0754 microM in all wells of column 24.

Negative control: No treatment in remaining empty wells of the assay plate (minimally, wells in column 23).
Comment: A threshold constant was calculated by subtracting 3.6 X experimental well standard deviation for absorbance from the experimental well average absorbance, combining all plates in a screening run. Well absorbance was then subtracted from this threshold value. Wells were considered active if the resulting value after subtracting the threshold constant > 0 for at least one replicate. Activity scores were calculated by subtracting well absorbance from negative control plate average absorbance, dividing by the difference between plate negative and positive control plate average absorbance, and multiplying by 100. Resulting values > 100 were set to 100 and < 0 were set to 0, where 100 = 100% activity.
Absorbance_AAbsorbance_BAbsorbance_AvgThreshold-Absorbance_AThreshold-Absorbance_B
0.7180.7170.7175-0.187986-0.186986
0.7320.720.726-0.201986-0.189986
0.6630.7090.686-0.132986-0.178986
0.6310.6880.6595-0.100986-0.157986
0.6840.6970.6905-0.153986-0.166986
0.7010.7060.7035-0.170986-0.175986
0.6950.6860.6905-0.164986-0.155986
0.6690.6990.684-0.138986-0.168986
0.650.7090.6795-0.119986-0.178986
0.6880.6750.6815-0.157986-0.144986
0.6770.6920.6845-0.146986-0.161986
0.660.7130.6865-0.129986-0.182986
0.6970.6830.69-0.166986-0.152986
0.6540.7120.683-0.123986-0.181986
0.6820.6840.683-0.151986-0.153986
0.6870.7060.6965-0.156986-0.175986
0.6680.6950.6815-0.137986-0.164986
0.70.7040.702-0.169986-0.173986
0.680.7030.6915-0.149986-0.172986
0.690.6870.6885-0.159986-0.156986
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1364-MLP_WT
Protocol: The day before screening, RN4220 was grown overnight (16-18 h) in sterile-filtered tryptic soy broth (TSB) at 30 degrees C with shaking.

On the day of screening, columns 1-24 of assay plates (Corning 3710, clear) were prefilled with 30 uL of TSB using the Combi. Next, 100 nL of each compound was pin-transferred to each plate. For every compound library plate, there were two daughter plates (A & B). Overnight cultures were diluted 625x into TSB. 50 uL of the diluted cultures were added to columns 1-24 of the corresponding assay plates. Wells in column 2 contained only medium (with culture) and served as the negative controls. Positive control (0.8 uL of erythromycin, 10 ug/mL) was added to column 1 using the Hewlett Packard D300. Final assay well volume was 80 uL. Plates were spun down and stacked 5 high, covered with lids (Corning 3009), and incubated at 30 degrees C overnight (~16 h).

The following day, assay plates were removed from the incubator and cell density quantitated using a PerkinElmer EnVision (600 nm filter).
Comment: Z-scores were calculated for every well based on plate average and standard deviation of experimental well absorbance (OD600). Wells were considered active for reduced WT survival if Z-score for both replicates <= -3 and absorbance for both replicates <= 0.18. Percent inhibition was calculated by subtracting well absorbance from negative control plate average absorbance, dividing by the difference between plate negative and positive control plate average absorbance, and multiplying by 100. The replicate values were then averaged to determine activity scores. Resulting values > 100 were set to 100 and < 0 were set to 0, where 100 = 100% activity.
Absorbance_WT_AAbsorbance_WT_BZ-score WT_AZ-score WT_BPercent Inhibition_WT_APercent Inhibition_WT_B
0.7370.747-1.624235685-1.0789525314.234071413.85068762
0.7480.834-1.4382629330.33116364814.991762772.84634982
0.8350.8340.0326124740.3311636482.922049772.84634982
0.7920.828-0.6943719230.2339142568.8875401023.68971273
0.9390.8961.7909003161.336074027-11.50611289-5.868400246
0.8210.844-0.204080120.4932459674.8643024361.440744971
0.8110.872-0.3731462590.9470764616.25162577-2.494948608
0.8230.872-0.1702668930.9470764614.58683777-2.494948608
0.7990.862-0.5760256250.7849941427.916413769-1.089343758
0.8480.8940.2523984541.3036575631.118529437-5.587279276
0.8410.8920.1340521571.2712410992.08965577-5.306158306
0.8660.8620.5567175040.784994142-1.378652562-1.089343758
0.8760.8650.7257836430.833618837-2.765975895-1.511025213
0.8370.8680.0664257020.8822435332.644585104-1.932706668
0.8380.8630.0833323160.8012023732.50585277-1.229904243
0.8120.844-0.3562396450.4932459676.1128934361.440744971
0.8150.877-0.3055198041.028117625.696696436-3.197751032
0.8650.8950.539810891.319865795-1.239920229-5.727839761
0.8310.88-0.0350139821.0767423163.476979103-3.619432487
0.8440.8450.1847719990.5094541991.673458771.300184486
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NIAID 靶标:N/A
External ID: HIV Cellular Data
Protocol: N/A
Comment: N/A
SpeciesStrainIsPseudotypeVirusAssayMethCellTypeCellType2TargetMutationsEC50ModEC50EC50UnitECOtherPctECOtherPctUnitECOtherConcECOtherConcUnitToxAssayMethToxCellTypeCC50ModCC50CC50UnitTIModTIRelResFoldChgCommentsReferenceCitationOther Information
HIV-1LAIRTHuT TK+HuT 78Reverse transcriptase<1uM100%1uMMTT>10uM>10HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID509281520USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405.
HIV-1MNRTHuT TK+HuT 78Reverse transcriptase<0.3uM76.74%0.3uMMTT>10uM>33.3HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 10 TCID509281520USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405.
HIV-1MNRTHuT TK+HuT 78Reverse transcriptase<0.3uM69%0.3uMMTT>10uM>33.3HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 100 TCID509281520USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405.
R5; CLINICAL ISOLATE1(JSL)P24PBMCReverse transcriptaseMDR0.07uM90%1uMMTT>100uM>1428HIV-1(JSL) WAS ISOLATED FROM PATIENTS WHO RECEIVED ANTIRETROVIRAL THERAPY FOR A LONG PERIOD AND WHOSE VIRUS ACQUIRED A NUMBER OF MUTATIONS IN THE RT- AND PR-ENCODING GENES; DETAILS OF MUTATIONS NOT GIVEN15280474SPIRODIKETOPIPERAZINE-BASED CCR5 INHIBITOR WHICH PRESERVES CC-CHEMOKINE/CCR5 INTERACTIONS AND EXERTS POTENT ACTIVITY AGAINST R5 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN VITRO. Journal of Virology 2004, 78(16), 8654-8662.ECOtherConcMod:>
HIV-1NL4-3LUCIFERASE1G5 TReverse transcriptase<1uM99%1uMTRYPAN BLUE>1uM>1ASSAY WAS CONDUCTED ON DAY 3 POST-INFECTION16725040INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP.CCOtherPct:6 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM
HIV-1NL4-3LUCIFERASE1G5 TReverse transcriptase<1uM99%1uMTRYPAN BLUE>1uM>1ASSAY WAS CONDUCTED ON DAY 5 POST-INFECTION16725040INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP.CCOtherPct:7 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM
HIV-1NL4-3LUCIFERASE1G5 TReverse transcriptase<1uM99%1uMTRYPAN BLUE>1uM>1ASSAY WAS CONDUCTED ON DAY 7 POST-INFECTION16725040INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP.CCOtherPct:3 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM
HIV-1LAVRTU1(THF-.alpha. STIM)U1Tumor necrosis factor alpha~30ug/mL70%50ug/mL>50ug/mL>1.66CHRONICALLY HIV-1 INFECTED PROMONOCYTE CELL LINE8327469THALIDOMIDE INHIBITS THE REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1. Proceedings of the National Academy of Sciences of the United States of America 1993, 90, 5974-5978.CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:50 | CCOtherConcUnit:ug/mL
HIV-1BaLP24 (DAY 18)MACROPHAGES(GM-CSF)MacrophageRibonucleotide reductase<10uM75%10uM>1000uM>10MAXIMAL P24 EXPRESSION AT DAY 187973634HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805.CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM
HIV-1BaLP24 (DAY 18)MACROPHAGES(GM-CSF)MacrophageRibonucleotide reductase<10uM38%2uM>1000uM>10MAXIMAL P24 EXPRESSION AT DAY 187973634HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805.CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM
HIV-1BaLP24 (DAY 18)MACROPHAGES(GM-CSF)MacrophageRibonucleotide reductase<10uM99%50uM>1000uM>10MAXIMAL P24 EXPRESSION AT DAY 187973634HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805.ECOtherPctMod:> | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM
HIV-1IIIBRTHT4(R116; AZT RESISTANT CELLS)HT4Reverse transcriptase~0.01uM70%0.01uM~`1uM~100FLOXURIDINE APPEARS TO POTENTIATE AZT ACTIVITY AND ALSO HAVE SOME ANTI-HIV ACTIVITY IN AZT RESISTANT CELL LINES8827211USE OF FLOXURIDINE TO MODULATE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. AIDS Research and Human Retroviruses 1996, 12(11), 965-968.ECOtherPctMod:~ | CCOtherPct:35 | CCOtherPctUnit:% | CCOtherConc:.1 | CCOtherConcUnit:uM
HIV-11.beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATIONHeLa H12(HIV-1 LTR-Laz, TAT)HeLaTat:TAR/LTR<0.1uM52%0.1uMTRYPAN BLUE>100uM>1000DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION9561563CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52.
HIV-11.beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATIONHeLa H12(HIV-1 LTR-Laz, TAT)HeLaTat:TAR/LTR<0.01uM78%0.01uMTRYPAN BLUE>100uM>10000DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION9561563CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52.
HIV-1IIIBSYNCYT FORMMOLT-4/H9(HIV-1(IIIB))MOLT-4gp120<1uM95%10uM-10010uM>10CHRONICALLY INFECTED H9 CELLS9343823TRIAZINE DYES INHIBIT HIV-1 ENTRY BY BINDING TO ENVELOPE GLYCOPROTEINS. Microbiology and Immunology 1997, 41(9), 717-724.CCOtherPct:30 | CCOtherPctUnit:% | CCOtherConc:10 | CCOtherConcUnit:uM
HIV-11.beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATIONHeLa H12(HIV-1 LTR-Laz, TAT)HeLaTat:TAR/LTR<0.01uM75%0.01uMTRYPAN BLUE>100uM>10000DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION9561563CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52.
HIV-11P24MT-4Integrase<0.25uM95%0.25uMMICROSCOPIC EXAMINATION>20uM>80IN THE PRESENCE OF 50% NHS16554152A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904.ECOtherPctMod:>
HIV-11P24MT-4Integrase<0.103uM95%0.103uMMICROSCOPIC EXAMINATION>20uM>194IN THE PRESENCE OF 10% FBS16554152A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904.ECOtherPctMod:>
HIV-1NL4-3RTMT-4Reverse transcriptase<1uM100%1uMWST-8>1uM>1MEASUREMENTS WERE MADE ON DAY 4, 6 AND 8 POST INFECTION15371436POLYARGININE INHIBITS GP160 PROCESSING BY FURIN AND SUPPRESSES PRODUCTIVE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION. The Journal of Biological Chemistry 2004, 279(47), 49055-49063.
HIV-1LAIRTHuT 78Reverse transcriptase<1uM57.14%1uMMTT>10uM>10MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID509281520USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1364-MLP_ugtP
Protocol: The day before screening, RN4220 ugtP was grown overnight (16-18 h) in sterile-filtered tryptic soy broth (TSB) at 30 degrees C with shaking.

On the day of screening, columns 1-24 of assay plates (Corning 3710, clear) were prefilled with 30 uL of TSB using the Combi. Next, 100 nL of each compound was pin-transferred to each plate. For every compound library plate, there were two daughter plates (A & B). Overnight cultures were diluted 625x into TSB. 50 uL of the diluted cultures were added to columns 1-24 of the corresponding assay plates. Wells in column 2 contained only medium (with culture) and served as the negative controls. Positive control (0.8 uL of erythromycin, 10 ug/mL) was added to column 1 using the D300. Final assay well volume was 80 uL. Plates were spun down and stacked 5 high, covered with lids (Corning 3009), and incubated at 30 degrees C overnight (~16 h).

The following day, assay plates were removed from the incubator and cell density quantitated using a PerkinElmer EnVision (600 nm filter). Library plates were screened in duplicate, with both assay plates in a given set prepared on the same day.
Comment: Z-scores were calculated for every well based on plate average and standard deviation of experimental well absorbance (OD600). Wells were considered active for reduced ugtP survival if Z-score for both replicates < -3 and absorbance for both replicates <= 0.15. Percent inhibition was calculated by subtracting well absorbance from negative control plate average absorbance, dividing by the difference between plate negative and positive control plate average absorbance, and multiplying by 100. The replicate values were then averaged to determine activity scores. Resulting values > 100 were set to 100 and < 0 were set to 0, where 100 = 100% activity.
Absorbance_ugtP_AAbsorbance_ugtP_BZ-score ugtP_AZ-score ugtP_BPercent Inhibition_ugtP_APercent Inhibition_ugtP_B
0.5140.537-1.229512579-0.52346704814.474576278.463841548
0.5470.588-0.7679522420.1914626568.508474576-0.932749885
0.6270.6070.3509819090.457809016-5.95480226-4.433440811
0.6140.6060.1691551090.443790786-3.604519774-4.24919392
0.6040.5740.02928834-0.004792557-1.7966101691.646706587
0.5640.55-0.530178735-0.3412300655.4350282496.068631967
0.6150.5740.183141786-0.004792557-3.7853107341.646706587
0.6170.6130.211115140.541918393-4.146892655-5.538922156
0.6010.604-0.012671690.415754327-1.254237288-3.880700138
0.7040.71.4279560291.761504358-19.87570621-21.56840166
0.6240.6150.3090218780.569954852-5.412429379-5.907415937
0.6450.6110.6027420930.513881934-9.209039548-5.170428374
0.5440.599-0.8099122730.3456631810.06359478-2.989036353
0.5620.617-0.5581520890.5979913116.850384916-6.312752452
0.5490.594-0.7399788880.2755720339.171036483-2.065781881
0.560.63-0.5861254420.7802282947.207408234-8.71321408
0.5690.545-0.46024535-0.4113212125.6008033026.982111945
0.5350.554-0.935792365-0.28515714711.670199715.320253895
0.5170.525-1.187552548-0.69168580214.8834095710.67512983
0.5130.534-1.243499256-0.56552173615.597456219.013271783
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1149-MLP
Protocol: A 558 bp region upstream of hspX was PCR amplified and cloned upstream of the GFP-mut2 (Cormack et al., 1996). This construct was cloned into a modified version of the replicating plasmid pSE100 and transformed into CDC1551 to generate CDC1551(hspX'::GFP).

The M. tuberculosis CDC 1551 (hspX'::GFP) fluorescent biosensor was grown in pH 7.0 Middlebrook 7H9 medium to mid- to late-log phase. Black-walled, clear-bottom, tissue-culture treated 384-well microtiter plates (Corning #3712) were filled with 25 uL of buffered pH 7.0 7H9 medium using a Matrix Combi. 100 nL of compound was then transferred to each well via stainless steel pin array. Plates were manually sealed with DMSO-resistant aluminum seals and frozen at -80C until they were ready to be screened. The cultures were re-suspended in pH 7.0 7H9 and 25 uL was dispensed into each well of the 384-well assay plates already containing the perturbator utilizing a Cy-Bio Selma liquid handler robot to an OD595 of 0.05. The plates were then placed in a Ziploc bag with a moistened paper towel (to limit evaporation) and incubated for 6 days at 37C. Fluorescence and optical density (OD) readings were made on an EnSpire plate reader (Perkin Elmer, Inc.) at excitation and emission wavelengths of 488 and 509 nm as a top read, with the OD being taken at 595 nm as a bottom read.

The ~328,633 compound library was arrayed into black-walled, clear-bottom tissue-culture treated 384-well microtiter plates (Corning #3712) by pin transfer (100 nL), containing 25 uL of buffered pH 7.0 7H9 medium. In a previous screen utilizing the same compound library and screening method, four random compound plates were screened in duplicate to observe variation in hit robustness across plates and method. The result was that the duplicate plates did not vary in a statistically significant manner and due to the high volume of compounds to be screened (~328,633), replicates were not utilized.

Negative control: DMSO, 0.1% final concentration in buffered pH 7.0 7H9 in column 2 or column 23 of each plate

Positive control: 0.3 uM Rifampicin final concentration in buffered pH 7.0 7H9 in column 1 or column 24 of each plate
Comment: Analysis methods:
To calculate normalized fluorescence percent inhibition, plate average negative control fluorescence intensity (based on all plates within a screening run) was subtracted from well fluorescence intensity, divided by the difference between plate negative and positive control average fluorescence intensity (based on all plates within a screening run), and multiplied by 100. To calculate normalized growth inhibition, plate average negative control absorbance (based on all plates within a screening run) was subtracted from well absorbance, divided by the difference between plate negative and positive control average absorbance (based on all plates within a screening run), and multiplied by 100. Normalized fluorescence percent inhibition was divided by normalized growth inhibition to calculate a ratio. Wells were considered active if growth was not greatly decreased and showed either a 3-fold selectivity fluorescence to growth inhibition ratio (with 35-45% fluorescence inhibition) or a 1.5-fold selectivity fluorescence to growth inhibition ratio (with > 45% fluorescence inhibition). These compounds may be directly or indirectly inhibiting DosRS signaling. Wells were considered general inhibitors of M. tuberculosis growth if both fluorescence and growth inhibition > 50%. Activity scores were scaled from 100 to 0 and derived from normalized fluorescence percent inhibition, with 100 (or > 100) = 100% inhibition and 0 (or < 0) = no inhibition.
FluorescenceAbsorbanceRatioNormalized Fluorescence InhibitionNormalized Growth InhibitionNormalized FI:GI RatioGeneral Inhibition
361550.2851268608.990745.250731.71228
367210.2811306807.519896.929291.08523
388660.291340211.945723.152540.617191
373140.281332645.978877.348930.81357
359490.2791288499.526077.768571.22623
359210.2871251609.598834.411462.17589
362680.2931237828.697091.893624.59283
392470.321226470.955621-9.43663-0.101267
386200.2861350352.584994.83110.535074
373510.2841315185.882725.670371.03745
380970.2831346183.94416.090010.647635
378520.2951283124.580781.054344.34468
372680.2981250606.09841-0.204574-29.8103
396530.284139623-0.09944285.67037-0.0175373
377440.2931288194.861441.893622.56727
377300.2871314634.897824.411461.11025
391230.3011299771.27786-1.46349-0.873157
366370.2871276557.738184.411461.75411
405660.327124055-2.47204-12.37410.199775
393340.2861375310.7295364.83110.151008